Medtronic (NYSE:MDT) Issues FY25 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $5.44-5.50 for the period, compared to the consensus estimate of $5.45. Medtronic also updated its FY 2025 guidance to 5.440-5.500 EPS.

Medtronic Price Performance

MDT stock opened at $87.64 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61. Medtronic has a 1 year low of $74.66 and a 1 year high of $92.68. The firm has a 50-day moving average of $89.42 and a 200 day moving average of $84.82. The company has a market cap of $112.39 billion, a P/E ratio of 29.61, a PEG ratio of 2.50 and a beta of 0.84.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. During the same quarter in the prior year, the company earned $1.25 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts forecast that Medtronic will post 5.44 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on MDT shares. Piper Sandler upped their target price on shares of Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Evercore ISI raised their price objective on Medtronic from $100.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Oppenheimer upped their target price on shares of Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 21st. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Monday. Finally, Barclays upped their price objective on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Medtronic currently has an average rating of “Hold” and an average price target of $95.80.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.